Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients.
Liu Z, Wu L, Cao J, Yang Z, Zhou C, Cao L, Wu H, Shen H, Jin M, Zhang Y, Mao X, Xiang J, Ma K, Li B, Zhang T, Hu Y.
Liu Z, et al. Among authors: cao j, cao l.
Onco Targets Ther. 2018 Oct 23;11:7323-7331. doi: 10.2147/OTT.S173391. eCollection 2018.
Onco Targets Ther. 2018.
PMID: 30425522
Free PMC article.